Starting this Monday, social security covers Mounjaro and Wegovy for patients with severe obesity or diabetes. It is a first in Europe.
The two drugs, GLP-1 analogues, are now reimbursed for eligible people. Patients could previously pay up to 500 euros per month out of pocket.
Dr Géraldine Skurnik, an endocrinologist, reports receiving about fifteen calls from patients in fifteen days. Another twenty, whose appointments were already scheduled, become eligible for reimbursement.
These treatments promise an average 15 % weight loss as long as the patient remains on treatment. This measure responds to strong demand among those concerned.
